Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II

Steven Hunt, Nancy R. Cook, Albert Oberman, Jeffrey A. Cutler, Charles H. Hennekens, P. Scott Allender, W. Gordon Walker, Paul K. Whelton, Roger R. Williams

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

The angiotensinogen gene has been linked to essential hypertension and increased blood pressure. A functional variant believed to be responsible for hypertension susceptibility occurs at position -6 in the promoter region of the gene in which an A for G base pair substitution is associated with higher angiotensinogen levels. To test whether an allele within the angiotensinogen gene is related to subsequent incidence of hypertension and blood pressure response to sustained sodium reduction, 1509 white male and female subjects participating in phase II of the Trials of Hypertension Prevention were genotyped at the angiotensinogen locus. Participants had diastolic blood pressures between 83 and 89 mm Hg and were randomized in a 2x2 factorial design to sodium reduction, weight loss, combined intervention, or usual care groups. Persons in the usual care group with the AA genotype at nucleotide position -6 had a higher 3-year incidence rate of hypertension (44.6%) compared with those with the GG genotype (31.5%), with a relative risk of 1.4 (95% Confidence interval [0.87, 2.34], test for trend across all 3 genotypes, P=0.10). In contrast, the incidence of hypertension was significantly lower after sodium reduction for persons with the AA genotype (relative risk=0.57 [0.34, 0.98] versus usual care) but not for persons with the GG genotype (relative risk=1.2 [0.79, 1.81], test for trend P=0.02). Decreases of diastolic blood pressure at 36 months in the sodium reduction group versus usual care showed a significant trend across all 3 genotypes (P=0.01), with greater net blood pressure reduction in those with the AA genotype (-2.2 mm Hg) than those with the GG genotype (+ 1.1 mm Hg). A similar trend across the 3 genotypes for net systolic blood pressure reduction (-2.7 for AA versus - 0.2 mm Hg for GG) was not significant (P=0.17). Trends across genotypes for the effects of weight loss on hypertension incidence and decreases in blood pressure were similar to those for sodium reduction. We conclude that the angiotensinogen genotype may affect blood pressure response to sodium or weight reduction and the development of hypertension.

Original languageEnglish
Pages (from-to)393-401
Number of pages9
JournalHypertension
Volume32
Issue number3
Publication statusPublished - Sep 1998
Externally publishedYes

Fingerprint

Angiotensinogen
Weight Loss
Sodium
Genotype
Blood Pressure
Hypertension
Incidence
Genes
Genetic Promoter Regions
Base Pairing
Nucleotides
Alleles
Confidence Intervals

Keywords

  • Blood pressure
  • Clinical trials
  • Genetics
  • Interaction
  • Prospective study
  • Renin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hunt, S., Cook, N. R., Oberman, A., Cutler, J. A., Hennekens, C. H., Allender, P. S., ... Williams, R. R. (1998). Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II. Hypertension, 32(3), 393-401.

Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension : Trials of hypertension prevention, phase II. / Hunt, Steven; Cook, Nancy R.; Oberman, Albert; Cutler, Jeffrey A.; Hennekens, Charles H.; Allender, P. Scott; Walker, W. Gordon; Whelton, Paul K.; Williams, Roger R.

In: Hypertension, Vol. 32, No. 3, 09.1998, p. 393-401.

Research output: Contribution to journalArticle

Hunt, S, Cook, NR, Oberman, A, Cutler, JA, Hennekens, CH, Allender, PS, Walker, WG, Whelton, PK & Williams, RR 1998, 'Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II', Hypertension, vol. 32, no. 3, pp. 393-401.
Hunt, Steven ; Cook, Nancy R. ; Oberman, Albert ; Cutler, Jeffrey A. ; Hennekens, Charles H. ; Allender, P. Scott ; Walker, W. Gordon ; Whelton, Paul K. ; Williams, Roger R. / Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension : Trials of hypertension prevention, phase II. In: Hypertension. 1998 ; Vol. 32, No. 3. pp. 393-401.
@article{003ece40337348a997458f1f6a839a84,
title = "Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II",
abstract = "The angiotensinogen gene has been linked to essential hypertension and increased blood pressure. A functional variant believed to be responsible for hypertension susceptibility occurs at position -6 in the promoter region of the gene in which an A for G base pair substitution is associated with higher angiotensinogen levels. To test whether an allele within the angiotensinogen gene is related to subsequent incidence of hypertension and blood pressure response to sustained sodium reduction, 1509 white male and female subjects participating in phase II of the Trials of Hypertension Prevention were genotyped at the angiotensinogen locus. Participants had diastolic blood pressures between 83 and 89 mm Hg and were randomized in a 2x2 factorial design to sodium reduction, weight loss, combined intervention, or usual care groups. Persons in the usual care group with the AA genotype at nucleotide position -6 had a higher 3-year incidence rate of hypertension (44.6{\%}) compared with those with the GG genotype (31.5{\%}), with a relative risk of 1.4 (95{\%} Confidence interval [0.87, 2.34], test for trend across all 3 genotypes, P=0.10). In contrast, the incidence of hypertension was significantly lower after sodium reduction for persons with the AA genotype (relative risk=0.57 [0.34, 0.98] versus usual care) but not for persons with the GG genotype (relative risk=1.2 [0.79, 1.81], test for trend P=0.02). Decreases of diastolic blood pressure at 36 months in the sodium reduction group versus usual care showed a significant trend across all 3 genotypes (P=0.01), with greater net blood pressure reduction in those with the AA genotype (-2.2 mm Hg) than those with the GG genotype (+ 1.1 mm Hg). A similar trend across the 3 genotypes for net systolic blood pressure reduction (-2.7 for AA versus - 0.2 mm Hg for GG) was not significant (P=0.17). Trends across genotypes for the effects of weight loss on hypertension incidence and decreases in blood pressure were similar to those for sodium reduction. We conclude that the angiotensinogen genotype may affect blood pressure response to sodium or weight reduction and the development of hypertension.",
keywords = "Blood pressure, Clinical trials, Genetics, Interaction, Prospective study, Renin",
author = "Steven Hunt and Cook, {Nancy R.} and Albert Oberman and Cutler, {Jeffrey A.} and Hennekens, {Charles H.} and Allender, {P. Scott} and Walker, {W. Gordon} and Whelton, {Paul K.} and Williams, {Roger R.}",
year = "1998",
month = "9",
language = "English",
volume = "32",
pages = "393--401",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension

T2 - Trials of hypertension prevention, phase II

AU - Hunt, Steven

AU - Cook, Nancy R.

AU - Oberman, Albert

AU - Cutler, Jeffrey A.

AU - Hennekens, Charles H.

AU - Allender, P. Scott

AU - Walker, W. Gordon

AU - Whelton, Paul K.

AU - Williams, Roger R.

PY - 1998/9

Y1 - 1998/9

N2 - The angiotensinogen gene has been linked to essential hypertension and increased blood pressure. A functional variant believed to be responsible for hypertension susceptibility occurs at position -6 in the promoter region of the gene in which an A for G base pair substitution is associated with higher angiotensinogen levels. To test whether an allele within the angiotensinogen gene is related to subsequent incidence of hypertension and blood pressure response to sustained sodium reduction, 1509 white male and female subjects participating in phase II of the Trials of Hypertension Prevention were genotyped at the angiotensinogen locus. Participants had diastolic blood pressures between 83 and 89 mm Hg and were randomized in a 2x2 factorial design to sodium reduction, weight loss, combined intervention, or usual care groups. Persons in the usual care group with the AA genotype at nucleotide position -6 had a higher 3-year incidence rate of hypertension (44.6%) compared with those with the GG genotype (31.5%), with a relative risk of 1.4 (95% Confidence interval [0.87, 2.34], test for trend across all 3 genotypes, P=0.10). In contrast, the incidence of hypertension was significantly lower after sodium reduction for persons with the AA genotype (relative risk=0.57 [0.34, 0.98] versus usual care) but not for persons with the GG genotype (relative risk=1.2 [0.79, 1.81], test for trend P=0.02). Decreases of diastolic blood pressure at 36 months in the sodium reduction group versus usual care showed a significant trend across all 3 genotypes (P=0.01), with greater net blood pressure reduction in those with the AA genotype (-2.2 mm Hg) than those with the GG genotype (+ 1.1 mm Hg). A similar trend across the 3 genotypes for net systolic blood pressure reduction (-2.7 for AA versus - 0.2 mm Hg for GG) was not significant (P=0.17). Trends across genotypes for the effects of weight loss on hypertension incidence and decreases in blood pressure were similar to those for sodium reduction. We conclude that the angiotensinogen genotype may affect blood pressure response to sodium or weight reduction and the development of hypertension.

AB - The angiotensinogen gene has been linked to essential hypertension and increased blood pressure. A functional variant believed to be responsible for hypertension susceptibility occurs at position -6 in the promoter region of the gene in which an A for G base pair substitution is associated with higher angiotensinogen levels. To test whether an allele within the angiotensinogen gene is related to subsequent incidence of hypertension and blood pressure response to sustained sodium reduction, 1509 white male and female subjects participating in phase II of the Trials of Hypertension Prevention were genotyped at the angiotensinogen locus. Participants had diastolic blood pressures between 83 and 89 mm Hg and were randomized in a 2x2 factorial design to sodium reduction, weight loss, combined intervention, or usual care groups. Persons in the usual care group with the AA genotype at nucleotide position -6 had a higher 3-year incidence rate of hypertension (44.6%) compared with those with the GG genotype (31.5%), with a relative risk of 1.4 (95% Confidence interval [0.87, 2.34], test for trend across all 3 genotypes, P=0.10). In contrast, the incidence of hypertension was significantly lower after sodium reduction for persons with the AA genotype (relative risk=0.57 [0.34, 0.98] versus usual care) but not for persons with the GG genotype (relative risk=1.2 [0.79, 1.81], test for trend P=0.02). Decreases of diastolic blood pressure at 36 months in the sodium reduction group versus usual care showed a significant trend across all 3 genotypes (P=0.01), with greater net blood pressure reduction in those with the AA genotype (-2.2 mm Hg) than those with the GG genotype (+ 1.1 mm Hg). A similar trend across the 3 genotypes for net systolic blood pressure reduction (-2.7 for AA versus - 0.2 mm Hg for GG) was not significant (P=0.17). Trends across genotypes for the effects of weight loss on hypertension incidence and decreases in blood pressure were similar to those for sodium reduction. We conclude that the angiotensinogen genotype may affect blood pressure response to sodium or weight reduction and the development of hypertension.

KW - Blood pressure

KW - Clinical trials

KW - Genetics

KW - Interaction

KW - Prospective study

KW - Renin

UR - http://www.scopus.com/inward/record.url?scp=0031656257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031656257&partnerID=8YFLogxK

M3 - Article

C2 - 9740601

AN - SCOPUS:0031656257

VL - 32

SP - 393

EP - 401

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3

ER -